Shengmai San for Treatment of Cardiotoxicity from Anthracyclines:A Systematic Review and Meta-Analysis  被引量:3

在线阅读下载全文

作  者:ZHANG Xiao-nan LI Yan-yang ZHANG Yuan-hui ZHANG Wan-qin ZHU Ya-ping ZHANG Jun-ping LV Shi-chao LIU Long-tao 

机构地区:[1]National Clinical Research Center for Chinese Medicine Cardiology,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing,100091,China [2]Tianjin Medical University Cancer Institute and Hospital,Tianjin,300060,China [3]First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin,300112,China

出  处:《Chinese Journal of Integrative Medicine》2022年第4期374-383,共10页中国结合医学杂志(英文版)

基  金:Supported by the National Natural Science Foundation of China(No.81973689,No.82074254);the Beijing Natural Science Foundation of China(No.7202176)。

摘  要:Objective:To systematically evaluate the efficacy of Shengmai San in patients with cardiotoxicity of anthracyclines.Methods:Randomized controlled trials(RCTs)were identified by searching China National Knowledge Infrastructure(CNKI),Wanfang Database,Chinese Biomedical Literature Database(CBM),Pub Med,Cochrane Library,and Embase Databases from the inceptions until December 2020.The Cochrane Handbook was used to evaluate the risk of bias in the included studies.Data analysis was conducted using Rev Man 5.3 software.Results:Totally 19 RCTs with 2,331 participants were included in this review.Results showed that in improving arrhythmia(13 RCTs,n=1,877,RR=0.37,95%CI 0.25 to 0.52,P<0.00001),the treatment group was superior to the control group.In terms of reducing left ventricular end-diastolic diameter(LVEDD,2 RCTs,n=128,MD=-0.79,95%CI-0.93 to-0.65,P<0.00001)and left ventricular end systolic diameter(LVESD,2 RCTs,n=128,MD=-0.58,95%CI-0.82 to-0.35,P<0.00001),the treatment group was also better than the control group.In reducing myocardial enzymes such as creatine kinase(CK)[(3 RCTs,n=256,SMD=-0.80,95%CI-1.16 to-0.44,P<0.0001),(2 RCTs,n=126,SMD=-0.62,95%CI-0.98 to-0.26,P=0.0007)],the treatment group was superior to the control group.Conclusion:Shengmai San has a positive effect on the treatment of cardiotoxicity from anthracyclines.However,in the future,it is still necessary to conduct high-quality RCTs to verify its efficacy.

关 键 词:Shengmai San ANTHRACYCLINES CARDIOTOXICITY systematic review META-ANALYSIS 

分 类 号:R285.6[医药卫生—中药学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象